Globin-Switching drug reduces sickle cell disease symptoms
Biotech Cellarity has dosed its first patient in a Phase I clinical trial of CLY-124, a first-in-class Globin-Switching oral medicine designed to treat sickle cell disease (SCD). “Initiation of our first-in-human clinical study for CLY-124 represents the delivery of our first clinical asset from our platform with… Read More